Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LipovaksinS4-EAH
- Development stage
- Phase 1
- Lead developer
- Bio Farma
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LipovaksinS4-EAH is a liposomal protein subunit vaccine candidate developed by PT Bio Farma for the prevention of tuberculosis. The vaccine utilizes the Lipovaxin platform, which employs a liposomal delivery system to enhance the immunogenicity of specific mycobacterial antigens. The 'EAH' component refers to a recombinant fusion protein comprising three key antigens from *Mycobacterium tuberculosis*: ESAT-6 (6 kDa early secretory antigenic target), Ag85B (Antigen 85B), and HspX (Heat shock protein X). This combination is designed to stimulate a comprehensive immune response, including both humoral and cellular immunity, to protect against TB infection and disease progression. The vaccine is currently being evaluated in Phase I clinical trials in Indonesia to assess its safety and immunogenicity in healthy adults.
- Other names
- Lipovaxin Tuberculosis VaccineLipovaxin-TB
02
Targets
Ag85B (Antigen 85B)HspX (Heat shock protein X)ESAT-6 (Early secretory antigenic target 6)
Beyond the preview
Go deeper on LipovaksinS4-EAH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LipovaksinS4-EAH.